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Abstract. 5-Aminolevelunic acid-induced protoporphyrin IX (PpIX) fluorescence-guided resection (FGR) ena-
bles maximum safe resection of glioma by providing real-time tumor contrast. However, the subjective visual
assessment and the variable intrinsic optical attenuation of tissue limit this technique to reliably delineating only
high-grade tumors that display strong fluorescence. We have previously shown, using a fiber-optic probe, that
quantitative assessment using noninvasive point spectroscopic measurements of the absolute PpIX concen-
tration in tissue further improves the accuracy of FGR, extending it to surgically curable low-grade glioma.
More recently, we have shown that implementing spatial frequency domain imaging with a fluorescent-light
transport model enables recovery of two-dimensional images of [PpIX], alleviating the need for time-consuming
point sampling of the brain surface. We present first results of this technique modified for in vivo imaging on an
RG2 rat brain tumor model. Despite the moderate errors in retrieving the absorption and reduced scattering
coefficients in the subdiffusive regime of 14% and 19%, respectively, the recovered [PpIX] maps agree within
10% of the point [PpIX] values measured by the fiber-optic probe, validating its potential as an extension or an
alternative to point sampling during glioma resection. © 2017 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10
.1117/1.JBO.22.7.076007]
Keywords: spatial frequency domain imaging; quantitative fluorescence imaging; protoporphyrin IX; diffuse reflectance spectroscopy;
glioma.
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1 Introduction
Neurosurgery is an integral component of treating patients with
glioma, a highly malignant brain tumor that arises from the glial
cells. If the tumor is operable, surgery is the first line of defense
and is also often used upon recurrence. The objectives are to
obtain tissues for accurate histopathologic classification and stag-
ing, to debulk the tumor, and to achieve complete or near com-
plete resection of the tumor as can be done safely. Our main
interest is to improve completeness of resection as, while patient
outcome including survival greatly depends on this, the success
rate remains low despite MRI guidance.1 In high-grade gliomas,
resecting >98% of the bulk tumor detected by MRI results in
improved progression-free survival rates and prolonged mean
overall survival,1 whereas low-grade gliomas are potentially cur-
able if complete resection is achieved.2 However, gliomas are usu-
ally infiltrative, so delineating the tumor margins and visualizing
any residual disease after tumor debulking are significant imped-
iments in both cases. This difficulty is further exacerbated by the
need to preserve normal brain tissue to retain maximum neuro-
logical function. As a result, there is a clinical need in neurosur-
gery for new highly sensitive and specific techniques for residual
cancer detection.
Intraoperative fluorescence-guided resection (FGR) has been
developed to enhance tumor visualization.3 While applicable
across many tumor sites, FGR has been most advanced in
glioma surgery, where it has been used both at the beginning
of surgery to define tumor/normal tissue boundaries and at
the near end of surgery (after debulking) to identify residual
tumor tissue in the resection bed as well as satellite tumors
that have migrated beyond the resection bed.3 Clinically,
FGR has resulted in a significant increase in complete resection
rates as estimated by MRI contrast enhancement postsurgery.4
The most widely used fluorophore in FGR of glioma is pro-
toporphyrin IX (PpIX), a precursor in the heme-biosynthesis
pathway that preferentially accumulates in tumor cells upon ad-
ministration of 5-aminolevelunic acid (ALA).5 There is gener-
ally excellent contrast between tumor and normal brain using
ALA-PpIX fluorescence detection.5 However, to date, fluores-
cence visualization as implemented commercially in, e.g., the
Zeiss Blue 400 neurosurgical microscope has been largely quali-
tative and subjective. This has limited resection of high-grade
tumors to only the “strongly fluorescing” regions, likely leaving
the more infiltrative components unresected. The qualitative
nature of the detected signals has also led to inadequate sensi-
tivity for reliable FGR of low-grade gliomas, which explains
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why PpIX FGR has been used clinically only for high-grade
disease.6
Significant challenges remain in making FGR a highly
sensitive and quantitative procedure, including accounting for
instrument-dependent distortions and calibrations and, more
importantly, correcting the “raw” fluorescence signal for the
marked effects of absorption and elastic scattering by the tissue
of both the excitation (usually in the blue spectral range for
PpIX, ∼400 to 450 nm) and emission light (usually> ∼ 630 nm
for PpIX). As tissue optical properties are highly variable, both
between patients and from point to point in each patient, it is
necessary to measure these at the same time and location as
the fluorescence measurements.6
We have developed several different platforms for quantita-
tive PpIX FGR, i.e., to measure and map the absolute PpIX con-
centration, [PpIX], in tissue.7–9 There are two main approaches:
semiempirical correction for tissue attenuation, typically using a
form of multiple-wavelength ratiometry, and rigorous correction
based on independent measurements of the tissue absorption
and scattering coefficients at the relevant wavelengths. This
study is an extension of two previous developments. The first
was the use of hyperspectral fluorescence imaging together
with semiempirical correction algorithms8,9 in which the use of
a high-sensitivity electron-multiplying charge-coupled detector
(EMCCD) enabled PpIX detection down to 10 ng∕ml in a
glioma model.9 The second development was based on an intra-
operative quantitative point-contact fiber-optic spectroscopy
probe7 that has been shown in clinical trials to significantly
improve the sensitivity and specificity of residual tumor tissue
detection in high-grade glioma and to make FGR of a low-grade
tumor feasible in patients.6 This intraoperative probe combines
fluorescence spectroscopy with diffuse reflectance spectros-
copy, where the latter is performed at two different source–
detector separations on the tissue surface, allowing the absorp-
tion and transport scattering spectra to be calculated by applying
a spectrally constrained light diffusion model.7 Using a spectral
unmixing algorithm, the background tissue autofluorescence
can be subtracted and, knowing the PpIX extinction spectrum,
[PpIX] can be calculated with an accuracy of about 10%
down to a concentration of 10 ng∕ml by correcting the fluores-
cence signal using a model-based attenuation factor with the
absorption and scattering coefficients as input parameters. This
instrument is currently undergoing multicenter clinical trials.
However, the point technique is clearly limited in practice by
undersampling of tissue, while the use of hyperspectral imaging
has unknown robustness given the inherent limitations of non-
modeled-based ratiometric techniques in terms of accuracy. The
goal here was to combine the strengths of rigorous quantifica-
tion with the speed of wide-field imaging. This requires map-
ping the tissue absorption and transport scattering coefficients,
μa and μ 0s , respectively, and using these values to compute an
attenuation correction factor for every imaged pixel.
Spatial frequency domain imaging (SFDI) is an emerging
wide-field technique that has the capability to extract quantita-
tive metrics relevant for fast and noninvasive diagnosis, such as
biochemical and structural composition of tissue.10 SFDI can
produce quantitative spatial maps of tissue absorption and scat-
tering properties by projecting sinusoidal light patterns of differ-
ent spatial frequencies, fx, onto the tissue surface by detecting
the spatially modulated diffuse reflectance images as a function
of frequency.10 As tissue effectively acts as a low-pass spatial
filter, the technique can be used to probe different tissue depths
and optical properties. At lower spatial frequencies, correspond-
ing to longer optical path lengths in the tissue, the modulation
amplitude is sensitive to both absorption and multiple scattering,
whereas at higher spatial frequencies, this amplitude is mostly
sensitive to scattering within relatively smaller penetration
depths.10 Detecting the diffuse reflectance at low and high spa-
tial frequencies is analogous to measuring the diffuse reflectance
at different source–detector separations using point detection
techniques but executed in the spatial frequency domain.11 In
the diffusion light transport regime, the spatially modulated dif-
fuse reflectance is fitted to a light diffusion model in the spatial
frequency domain to solve inversely for μa and μ 0s . A detailed
description of SFDI to recover tissue optical properties is pre-
sented in Ref. 10. In the operating room, the utility of SFDI as a
quantitative tissue analyzer has been applied in reconstructive
surgery, where the metric of interest is real-time measurement
of the hemoglobin oxygenation status and content to assess tis-
sue viability.12,13 More recently, the measured tissue scattering
has been used to better identify tumor margins during breast
conservative surgery, based on structural differences between
tumor and normal tissue.13
A potential application of SFDI is leveraging its capabilities
toward achieving quantitative, wide-field FGR. An ex vivo study
by Yang et al.14 used SFDI to correct the measured fluorescence
images for the effects of tissue absorption, by normalizing the
spatially modulated fluorescence images by the corresponding
diffuse reflectance images at a relatively high spatial frequency
of 0.5 mm−1. Perhaps more relevant to the development of FGR,
a preclinical glioma study by Konecky et al.15 exploited the sec-
ondary absorption peak of PpIX at 635 nm to excite tissue with
red-light patterns (enabling greater penetration in tissue) and
applied a tomographic approach to decouple [PpIX] from the
tumor depth. A significant limitation is that an approximate
measure of depth needs to be known a priori.15 To our knowl-
edge, no other in vivo study has reported the use of SFDI for
quantitative PpIX fluorescence imaging under the conditions
of FGR as it is currently practiced in neurosurgery, i.e., subdif-
fusive imaging under violet/blue light excitation. Other studies,
such as Saager et al.,16 utilized near-infrared excitation and fluo-
rescence detection in the fully diffusive regime, where autofluor-
escence and PpIX photoproducts were not spectrally separated
from the intrinsic PpIX fluorescence signal, thereby producing
only relative estimates of [PpIX]. One potential issue for PpIX
FGR is that the optical properties of malignant brain tissue in
the violet/blue wavelength range lie in the subdiffusive
regime,6 where μa ∼ μ 0s , render the reduced transport albedo,
a 0 ¼ μ 0sðμaþμ 0sÞ ≪ 1, so standard diffusion theory may not be suf-
ficiently accurate. This definition of subdiffusive regime is not
to be confused with subdiffuse scattering, where photons
are detected after only a single or few scattering events
occur. In that case, scattering parameters characterizing ultra-
and microbiostructures are of interest (see, for example,
Kanick et al.17).
We present our first results of implementing spatial fre-
quency domain–enabled quantitative fluorescence imaging
(SFD-qFI) in an intracranial glioma model in rats, extending
our previous work in tissue-simulating phantoms.18 In that
work, we demonstrated the ability to recover μa and μ 0s in the
subdiffusive regime with accuracies of 8% and 13%,
respectively.18 Here, a model-based SFDI algorithm is used
for two-dimensional (2-D) mapping of the wavelength-depen-
dent tissue optical properties, μa and μ 0s , in the brain/tumor,
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and these are then used as inputs to a fluorescent-light transport
model to convert the raw fluorescence images to absolute [PpIX]
images. We show that, while the diffusion-based SFDI model
has limited accuracy in deriving the tissue optical properties
in the subdiffusive regime, we can nevertheless map [PpIX] with
similar sensitivity and accuracy to our gold-standard point-probe
system.
2 Materials and Methods
2.1 Quantitative Point Fluorescence Spectroscopy
The right side of Fig. 1(b) shows the intraoperative probe affixed
to a vertical 3-D translation stage. This instrument has been
described in detail previously.19 Briefly, the probe consists of
four 200-μm core-diameter optical fibers spaced 260-μm apart
center to center; two fibers are attached to broadband white light
sources; one is attached to a blue/violet light-emitting diode
(LED) centered at 405 nm, and the other is a collection fiber
connected to a spectrometer.19
The measured diffuse reflectance for each source–detector
separation is fitted to the spectrally constrained diffuse reflec-
tance predicted by diffusion theory. The spectral shapes of μa
and μ 0s are assumed to be known a priori for a given tissue
type and serve as fitting constraints: hemoglobin is assumed
to be the dominant absorber, while the transport scattering fol-
lows an inverse power law as a function of wavelength. For exci-
tation at 400 to 440 nm, where PpIX and hemoglobin absorption
are high, the remitted fluorescent photons, Fm, detected at 600
to 720 nm can be assumed to travel similar path lengths to those
for the diffuse reflectance signal, Rm, in the same wavelength
range. Hence, Fm is proportional to Rm multiplied by the frac-
tion of excitation photons that are absorbed by PpIX and that
produce fluorescence. Knowing the main endogenous fluoro-
phores in brain tissue [(nicotinamide adenine dinucleotide
(NADH), lipofuscin, and flavin adenin dinucleotide (FAD)]
the total quantitative fluorescence signal is then spectrally
unmixed to separate PpIX fluorescence from autofluorescence
as well as from any PpIX photoproducts generated during sur-
gical exposure of the tissue. Given the known PpIX extinction
spectrum, the corrected PpIX spectrum can then be used to
determine [PpIX]. In this work, we apply the algorithm devel-
oped for point measurements to achieve SFD-qFI.
2.2 Quantitative Reflectance Imaging
2.2.1 SFDI and experimental setup
A detailed description of the SFD-qFI system has been pre-
sented previously.18 Briefly, illumination comprises six LEDs
(Spectra X: Lumencor, Beaverton, Oregon) centered at 390,
440, 475, 512, 586, and 632 nm and coupled to a 3-mm-diam-
eter liquid light guide (LGG0338, ThorLabs, Montreal, Canada)
to project the light onto a spatial light modulator (Digital
Micromirror Device, 0.55XGA Series 450 DMD, Texas
Instruments, Dallas, Texas) from which it is reflected onto
the sample. The imaging system consists of a 14-bit charge-
coupled device (CCD; Pixelfly, PCO AG, Kelheim, Germany)
connected to a visible-range liquid crystal tunable filter (LCTF,
varispec-07-02: Perkin Elmer, Waltham, Massachusetts) by a
2∶1 relay C-mount lens. This optimally fills the CCD field
of view across the rat brain (∼2 cm × 2.5 cm). Crossed polar-
izers are included in both the projection and imaging paths
to reduce specular reflection. Eight spatial frequencies, ranging
from 0 to 1.0 mm−1 (0, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, and 1 mm−1)
are projected at three spatial phases, 0, 2π∕3, and 4π∕3 to re-
cover the demodulated diffuse reflectance images. It takes ∼12 s
to collect one set of images per phase shift for 32 wavelengths
from 400 to 720 nm in 10-nm steps. Figure 1 shows a schematic
diagram and photograph of the SFD-qFI system with a rat
affixed to the stereotaxic animal holder. Adjacent to the imaging
system is the 3-D translational stage used to sample the brain
surface with the contact probe to serve as the reference standard
for local [PpIX] measurements.
2.2.2 SFDI implementation and recovery of μa and μ 0s
The structured light illumination patterns projected on the brain
surface are sinusoids of the form
EQ-TARGET;temp:intralink-;e001;326;378Iiðx; yÞ ¼ IDC þ A × cosð2πfx × xþ φiÞ; (1)
with phase offsets of ϕi ¼ ½0; 2π3 ; 4π3  for i ¼ 1, 2, 3. fx is the
spatial frequency in mm−1, IDC is the direct current (DC) com-
ponent of the excitation light, and A is the modulation depth.10
For each pixel, the modulated alternating current (AC) reflec-
tance, MAC, is calculated from the set of intensity images as
(a) (b) (c)
Fig. 1 SFD-qFI setup: (a) schematic diagram showing the liquid light guide, DMD, lenses (L1, L2), mirror
(M), LCTF, CCD, and the sample stage, (b) photograph of the system as well as the point probe mounted
on a 3-D translation stage, and (c) close-up of a rat affixed to the stereotaxic frame with the probe
positioned for point qFS measurements.
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EQ-TARGET;temp:intralink-;e002;63;752MACðxi; fxÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2 × f½I1ðxÞ − I2ðxÞ2 þ ½I1ðxÞ − I3ðxÞ2 þ ½I2ðxÞ − I3ðxÞ2g
3
r
: (2)
The modulated DC reflectance amplitude, MDC, is obtained
from the average of the three phase-shifted intensity images for
the same fx,
EQ-TARGET;temp:intralink-;e003;63;654MDCðxiÞ ¼
I1ðxiÞ þ I2ðxiÞ þ I3ðxiÞ
3
: (3)
The calibrated demodulated reflectance, Rsampled , is deter-
mined from the ratio of the demodulated AC intensity measured
on the sample, MsampleAC , to the demodulation image obtained by
projecting the same spatial frequencies onto a reference standard
of known optical properties, MrefAC, multiplied by the diffuse
reflectance, Rrefd , of that standard, as predicted by diffusion
theory or determined by Monte Carlo simulations. Thus,
EQ-TARGET;temp:intralink-;e004;63;535
sample
d ðxi; fxÞ ¼
MsampleAC ðxi; fxÞ
MrefACðxi; fxÞ
× Rrefd ðxi; fxÞ: (4)
Using Eq. (4), the modulation response of the imaging system
itself is decoupled from the tissue response, so μa and μ 0s can
then be extracted by inversely to solve the spatially resolved dif-
fusion equation in the SFD.10
2.3 Quantitative Fluorescence Imaging
The blue LED centered at 440 nm is used to induce PpIX fluo-
rescence. Hyperspectral fluorescence images are acquired for
300 ms per wavelength from 600 to 720 nm in increments of
10 nm. Planar diffuse reflectance images at the excitation and
emission wavelengths, Rx (at 440 nm) and Rm (at 640 nm),
as well as 2-D maps of μa;x and μ 0s;x are recovered by SFDI
[Eqs. (1)–(4)]. Those values are then used to retrieve the quan-
titative fluorescence qf for each pixel using the formula7
EQ-TARGET;temp:intralink-;e005;63;329qfx;mðx; y; λÞ ¼
μa;xðx; yÞ × Fmðx; y; λÞ
½1 − Rxðx; yÞ × Rmðx; y; λÞ
: (5)
[PpIX] is extracted on a pixel-by-pixel basis in the same manner
as for the point spectroscopy probe, yielding 2-D maps of
[PpIX] that can be overlaid on the diffuse reflectance images.
2.4 Postmortem and In Vivo Imaging
2.4.1 Tumor induction
Female Fischer 344 rats (Envigo, Maryland) were used under
institutional approval (University Health Network, Toronto,
Canada). For tumor induction, the rats were anesthetized
using a nose cone with 4% isoflurane in oxygen at 2 L∕min
and maintained by 1% to 2.5% isoflurane at 1 L∕min. The
eyes were lubricated with tear gel and the animals were placed
on a warming pad. The scalp was shaved and disinfected with
betadine and isopropanol, followed by a 1.5-cm incision along
the midline to retract the scalp. A 1-mm burr hole was made in
the left cranium, 3 mm posterior to the bregma and 3 mm to the
left of the sagittal suture, exposing the dura but leaving it intact.
Subsurface intracranial brain tumors were induced by injecting
105 RG2 (ATCC CRL-2433) cells in 5 μL in Neurobasal-A
media (Life Technologies, Massachusetts) through the burr
hole to a depth of either 0.5 mm or 1.5 to 2 mm below the
dura using a 30G Hamilton Neuros syringe. The burr hole
was then closed with bone wax. After surgery, the animals
were monitored continuously until full recovery, and buprenor-
phine (0.05 mg∕kg SQ) was administered for analgesia every
12 h for the first 72 h. Tumors were allowed to grow for 13
to 16 days to 2- to 4-mm diameter.
2.4.2 In situ and in vivo imaging
In vivo imaging after removing the dura proved to be subopti-
mal, as this caused excessive bleeding that had to be continu-
ously cleared with saline. Hence, craniotomy followed by
SFD-qFI was performed immediately after euthanasia for the
first set of rats (N ¼ 6) for which cancer cells were injected
1.5- to 2-mm deep. This will henceforth be referred to below
as in situ imaging. The craniotomy and removal of the dura
were necessary in these animals to visualize the bulk tumor that
tended to grow more axially (downward) than laterally. A sec-
ond set of rats (N ¼ 2) was used to test the feasibility of actual in
vivo imaging. In this case, cancer cells were injected superfi-
cially (∼0.5-mm deep), allowing in vivo imaging following
removal of the bone flap but not of the dura, thereby avoiding
excessive bleeding.
On the day of surgery, a 50 or 100 mg∕kg body weight (BW)
dose of ALA (Sigma-Aldrich, Ontario, Canada) was injected
intraperitoneally and the rats were then kept under subdued
light for 1 h. For in situ imaging, the animals were sacrificed
using 120 mg∕kg BW of euthanyl (sodium pentobarbital
240 mg∕mL) via the tail vein under general anesthesia. The
skull and dura were rapidly removed to expose the tumor.
Each rat was immediately affixed to the stereotaxic animal
frame and positioned for imaging [Fig. 1(b)]. Fiducial markers
were placed in a lateral line across the brain [Fig. 2(c)] to guide
the point qFS measurements in steps of 0.4 mm, sampling the
tumor as well as adjacent region and the contralateral normal
brain. Following qFS, planar hyperspectral fluorescence images
were acquired under blue light excitation. White light SFDI was
also performed using eight spatial frequencies up to 1 mm−1 and
SFD-qFI analysis was performed on three regions of interest
(ROI) spanning the qFS point measurements: tumor, adjacent,
and contralateral brain.
For the in vivo imaging, craniotomy was performed at 1 h
after ALA injection, under the same general anesthesia as
used for cancer cell injection. The scalp was shaved and beta-
dine was applied. The bone flap was carefully removed keeping
the dura intact. A pulse oximeter was used to monitor heart rate
and oxygen saturation. The same steps followed for postmortem
imaging were then followed. Multiple probe measurements were
taken over both the tumor and the contralateral side. Post SFD-
qFI, the rats were sacrificed by 120 mg∕kg euthanyl injection
via the tail vein.
2.4.3 Ex vivo imaging
After letting the tumors grow for 13 to 16 days, 100 mg∕kg
ALA was injected 1 h prior to sacrifice as described above.
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The whole brain (N ¼ 4) was removed intact and 2 to 3-mm-
thick coronal sections were cut at the tumor boundaries. The
same imaging sequence used for in vivo imaging was followed,
with the tissue section sampled first by qFS and then by
SFD-qFI.
3 Results
Figure 2 shows examples of the raw in situ fluorescence images
at 635 nm overlaid on the diffuse reflectance images at the same
emission band under white light illumination as well as the cor-
responding [PpIX] map for the tumor regions. In the first two
rats that had 2-mm depth of tumor cell injection, a thin layer of
overlying normal brain was first resected to expose the tumor
surface; this was not required in the remaining rats where the
cells were injected only 1.5 mm below the dura so that the tumor
grew up to the superficial layers of the brain surface. Although
the rats were matched as much as possible in weight and age,
there were marked variations in tumor size and degree of infil-
tration: e.g., rat #2 had two tumor foci in which one showed
no visible fluorescence but the corresponding [PpIX] image
showed comparable concentration as the tumor that was visible
under qualitative fluorescence imaging. Fluorimetry measure-
ments in ex vivo tissue samples from both right and left foci
confirmed the presence of tumor and significant [PpIX], corre-
sponding to the SFD-qFI results.20 SFDI analysis showed that μa
was five times higher in the nonvisualized tumor (2.8 versus
0.56 mm−1 at 450 nm) due to greater hemoglobin content.
This demonstrates clearly the value of the qFS approach in
accounting for variable tissue optical properties, as we have
observed also in patients using the point probe.6 On the other
hand, the quantitative [PpIX] map for rat #1 showed a more
heterogeneous PpIX accumulation across the tumor compared
with the raw fluorescence image [Fig. 2(b)]. Additionally, the
[PpIX] image showed higher tumor-to-normal contrast, particu-
larly at the tumor boundary, compared with the more diffuse
boundary apparent in the raw fluorescence image. In rat #3,
the center of the tumor exhibited a raw fluorescence intensity
that was 2.5 times higher than at the boundary, while the
[PpIX] map showed a more uniform distribution (variation of
only 1.5-fold), while still depicting local heterogeneity through-
out the tumor.
The local [PpIX] variations in rat #3 are further shown in
Fig. 3(b), where profiles of μa, μ 0s , and [PpIX] are plotted
along the line of the point-probe measurements from left to
right [dashed line in Fig. 3(a)]. All three profiles show good cor-
respondence between the SFDI and point-probe measurements
and illustrate also the heterogeneity of the calculated [PpIX]
maps compared with the raw fluorescence images, with signifi-
cant PpIX present in the tissue adjacent to the tumor core, indi-
cating tumor infiltration.
Ex vivo measurements were performed in intact resected
brain (rats #4 and 5) to validate the coregistration between qFI
and qFS measurements. The tumor slices shown in Fig. 4(a)
were oriented so that the top surface of the brain was positioned
at the bottom of the image. The white light image shows a rel-
atively dark and homogeneous tumor with a major blood vessel
in the middle (estimated to be 0.4 mm below the surface by
counting the number of pixels between the tumor boundary
and the bottom edge of the tissue). The raw fluorescence
image shows a step-like variation in the PpIX fluorescence,
in marked contrast with the actual [PpIX] maps, where the
higher [PpIX] at the middle of the tumor is correlated
with higher tissue absorption coefficient [5 versus 1 mm−1:
Figs. 4(d)–4(f)]. This is consistent with greater PpIX accumu-
lation in regions with higher microvascular density. The bright
granularity seen in (d) and (e) is in part an artifact due to light
(b) (c)(a)
Fig. 2 In situ imaging: (a) raw fluorescence images overlaid on diffuse reflectance images, showing dif-
ferent tumor sizes and levels of infiltration, (b) and (c) show, respectively, magnified raw fluorescence
images at 640 nm and derived [PpIX] images within tumor ROI indicated by the red dashed zones in (a).
The intensity values on the color bars for raw fluorescence varied from 0 to 9, 0 to 3, and 0 to 6 for rats #1
to 3, respectively. [PpIX] values on the color bars for the third column varied from 0 to 5 μg∕ml, 0 to
2 μg∕ml, and 0 to 1 μg∕ml for rats #1 to 3, respectively.
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Fig. 3 Comparison of SFDI and qFS profiles: (a) raw fluorescence overlaid on the diffuse reflectance
image for rat #3 showing the tumor with hyperintense core (yellow) and surrounding diffuse signal at the
tumor boundaries (green). The two black regions are pieces of surgical tape used to guide the point-probe
translation, and (b) profiles (solid lines) of SFDI-derived μa and μ 0s at 450 nm and [PpIX] compared with the
qFS measurements indicated by *, also calculated at 450 nm. Note that the tissue optical properties and
[PpIX] values are absolute and have not been normalized between the two groups of measurements.
Fig. 4 Example of ex vivo fluorescence and reflectance images (rat #4): (a) white light image of 3-mm
thick coronal section: the tumor is located to the left of the black mark (tumor extent is depicted by two
arrows) in this frame, (b) raw diffuse reflectance imaged at 620 nm with the tumor ROI indicated by the
dashed box. Color bar intensity values varied from 0 to 90 (au), (c) raw fluorescence image (440-nm
excitation and 635-nm emission) of the ROI shown in (b). Color bar intensity values varied from 0 to
8 (au), (d) corresponding SFD-qFI-derived image of [PpIX], which varied from 0 to 5 μg∕ml, (e) quanti-
tative μa map at 450 nm in the ROI obtained from SFDI, where values varied from 0 to 6 mm−1, and
(f) corresponding [PpIX] profile calculated as the mean value of each column in (d) from SFD-qFI
(solid line) and probe measurements (points).
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absorption by black flocked self-adhesive paper (TB4, Thorlabs,
Montreal, Canada) used to minimize back scattering.
Figure 5 shows an example of in vivo imaging in a rat #6
bearing a superficial intracranial tumor of 2.2-mm diameter
as determined by preoperative MRI. The raw fluorescence at
635 nm could not be overlaid onto the diffuse reflectance
image in Fig. 5(a) due to the specular reflection from the dura
despite using crossed polarizers. However, the region around the
tumor did not have any nearby specular reflection-induced pixel
saturation. The mean absorption and reduced scattering coeffi-
cients of the tumor at 450 nm were 1.26 0.09 mm−1 and
2.98 0.14 mm−1, respectively, whereas the mean [PpIX] in
the tumor was 1.45 0.25 μg∕ml. The corresponding values
from the point-probe measurements were 1.28 0.38 mm−1,
2.26 0.72 mm−1, and 1.25 0.56 μg∕ml.
In Fig. 6, the mean μa, μ 0s , and [PpIX] across the ROI for each
rat are plotted against the values determined by the point probe,
with the error bars indicating the standard deviation of each
parameter within the tumor ROI for each rat. μa and μ 0s at
405 nm, determined by qFS and applied to calculate [PpIX],
were then recalculated at 450 nm to make the comparison
with those obtained by SFDI at the same wavelength more accu-
rate (Fig. 6). The error bars for qFS are generally larger than
for SFDI, likely because of the spatial heterogeneity of the
PpIX fluorescence and the relative undersampling of the point
probe (typically 10 locations) compared with the wide-field im-
aging, where each standard deviation was derived from 50 to
100 pixel values. The large error bars in μa and [PpIX] for
rat #4 for both SFD-qFI and qFS are due to the high blood con-
tent in part of the tumor, similar to the ex vivo example shown in
Fig. 4, whereas the measurements for rat #6 were taken in vivo.
There was no systematic trend between the absorption coeffi-
cient values measured by each technique, but the SFDI method
appeared to somewhat overestimate the tissue scattering. This is
probably due to the different source–detector separations used in
qFS and SFDI, the former being the specific separations of 0.26
and 0.52 mm and the latter being dependent on the projected
spatial frequency, which correspond to radial separations of
0.15 up to 3.15 mm. Specifically, the smaller source–detector
separation of 0.15 mm at the higher spatial frequencies used
in SFDI will be more sensitive to detecting higher scattering
events.
The mean relative differences between measuring μa and μ 0s
by SFDI and qFS were 14% and 19.4%, respectively, probably
due to the larger tissue volumes interrogated by SFDI at 440 nm
compared with the point probe. The mean penetration depth of
405-nm excitation light in brain tissue is ∼0.25 mm, whereas
the mean penetration depth at 440-nm excitation light is
∼0.45 mm as estimated by Monte Carlo. However, these
differences did not propagate fully into the calculated PpIX
maps, where the mean relative difference was 10.5% for μa
and μ 0s over the range of 0.2 to 5 mm−1, and there was no sys-
tematic difference apparent. Hence, there may be a degree of
“self-correction” in the derived values for [PpIX]. Moreover,
(a) (b) (c)
(d) (e)
Fig. 5 In vivo quantitative imaging: (a) diffuse reflectance at 620 nm with the dura intact and the super-
ficial tumor located within ROI indicated by the dashed box. The saturated regions are due to specular
reflection (indicated by arrows), (b) raw fluorescence image at 635 nm in the ROI, (c) corresponding
[PpIX] map, (d) μa map at 450 nm, and (e) μ 0s map at 450 nm.
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statistical analysis showed that there is no significant difference
in the values of μa (p ¼ 0.586), μ 0s (p ¼ 0.708), and [PpIX]
(p ¼ 0.760) calculated by qFS and SFD-qFI at the 95% signifi-
cance level. Finally, a third independent and well-established
method for measuring [PpIX], based on fluorescence spectros-
copy of ex vivo homogenized tissue,20 correlated well with both
qFS and qFI (p > 0.1).
4 Discussion and Conclusions
The goal of fluorescence guidance during (brain) tumor surgery
is to maximize the completeness of tumor resection to limit
recurrence and increase the efficacy of subsequent chemothera-
peutic agents and radiation therapies. Because of the invasive
and diffusive nature of gliomas as well as the need to preserve
functional tissue, achieving optimal tumor resection is difficult
using standard-of-care surgical approaches based on white light
visualization combined with preoperative or intraoperative
MRI.1–4 Qualitative ALA-PpIX fluorescence imaging during
resection provides superior tumor-to-normal contrast, resulting
in improved completeness of resection and survival outcomes
for patients with high-grade glioma.1–4 However, it has not
been sufficiently robust in the case of low-grade gliomas that
generally have much lower PpIX concentrations, and even in
high-grade disease, the subjective and qualitative interpretation
of the fluorescence imaging has limited the resection to areas of
“strong” fluorescence.1 These characteristics of qualitative
ALA-PpIX fluorescence imaging are an impediment to consis-
tent dissemination and clinical adoption of the technique. The
high light attenuation of tissues, particularly for the violet/
blue wavelengths of PpIX fluorescence excitation, severely
limits quantification of the PpIX concentration in vivo.6
Using an intraoperative point fluorescence/diffuse reflectance
probe, quantitative measurements have been realized, demon-
strating increased sensitivity and specificity in detecting residual
tumor tissue at the end of white light resection as well as
detecting nonvisible fluorescence from low-grade gliomas.6
However, such point-by-point sampling is time consuming
(although each measurement is done in a fraction of a second),
and undersampling may result in missing residual tumor tissue.
Hence, there is interest in rapid, wide-field quantitative fluores-
cence imaging, especially if this can achieve comparable
accuracy as the point measurement approach. This has been
demonstrated here in a preclinical glioma model in rats using
a full model-based approach enabled by SFDI.
Due to the infiltrative nature of the RG2 tumor model, a
larger portion of the bulk tumor grew deeper (>1.5 mm) than
initially intended, so full craniotomy and, in two cases, removal
of superficial brain tissue (rats #1, 2) was required. Removal of
the dura to reduce specular reflection artifacts caused excessive
bleeding, which overwhelmed the in vivo fluorescence and
reflectance images (rat #6). These problems necessitated modi-
fication of the experimental protocol, including the use of in
situ/postmortem and ex vivo measurements (rats #4, 5).
However, these are limitations of the rat glioma model rather
than of the method or instrument and will not apply in the clinic.
Although the accuracy of the recovered tissue optical properties
and [PpIX] using SFD-qFI was somewhat less than with the
point-probe technique, the only systematic error was the slight
overestimation of the scattering coefficient. The quantitative im-
aging also clearly revealed the intratumoral heterogeneities in
both the tissue optical properties and the PpIX concentration.
The minimum [PpIX] value detected by SFD-qFI from the in
situ rat brain images was 44 ng∕ml in tumor and 13 ng∕ml in
normal brain. These should be compared with 11 and 8.6 ng∕ml
determined by qFS. The loss of sensitivity may be due in part to
“spill over” or cross talk between image pixels and in part to
sampling larger tissue volumes that introduces more tissue-
related distortion and attenuation of weak fluorescent signals.
Nevertheless, compared with the raw fluorescence images,
extracting the true [PpIX] values significantly improved the sen-
sitivity, allowing detection of nonvisible fluorescent tumor, as
seen by the example of rat #2 (Fig. 2). Moreover, the quantita-
tive PpIX maps showed enhanced tumor-to-normal contrast as
seen by the example of rat #1 and true tumor extent as seen in the
example of rat #3 (Fig. 2). It is important to note the differences
in the sampled tissue volumes measured by each method as well
as the differences in PpIX’s fluorescence quantum efficiency.
Both differences stem from the difference in the excitation
wavelengths (405 versus 440 nm) used for qFS compared
with SFD-qFI. PpIX has its maximum absorption coefficient
at 405 nm, whereas the 440-nm planar excitation will have a
larger penetration depth (0.45 versus 0.25 mm) and more
Fig. 6 Scatter plots of the mean values for μa, μ 0s, and [PpIX] derived
by SFD-qFI against the values obtained from qFS for in situ (rats #1 to
3), ex vivo (rats #4, 5), and in vivo (rat #6) measurements. The errors
are the 1 standard deviation within the tumor ROI. The lines of iden-
tity are also indicated (dashed lines).
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excitation light is available to be absorbed by the tumor during
wide-field imaging. As the three quantitative parameters were
not seen to be significantly different when measured by the
probe versus SFDI, the longer penetration depth during wide-
field imaging may have compensated for the suboptimal exci-
tation wavelength.
This study also showed an added advantage of SFD-qFI over
not only conventional qualitative FGR but also point qFS. The
[PpIX] maps recapitulate the true PpIX distribution across the
whole tumor, which is known to vary with ALA uptake and
differences in the heme-biosynthesis pathway. A common
observation in all rats was that the PpIX accumulation was sig-
nificantly higher in regions with higher blood content, as seen
by comparing the [PpIX] and μa maps in Fig. 4. Several other
studies have shown a similar relationship between microvascu-
lar density and [PpIX].21–23 For example, Valdes et al.21 used
surgically biopsied tissue to measure gadolinium (Gd) concen-
tration (used in MRI) against [PpIX] in visible and nonvisible
fluorescent tumor samples from nine patients with varying
glioma grade. For each biopsy, a third sample was prepared
for immunohistochemistry of microvascular density.21 Not
only did the ex vivo Gd concentration correlate strongly with
increased microvascular density, as expected, but also with
the [PpIX] levels in both qualitative FGR-visible and nonvisible
tumors, suggesting a common mechanism of vasculature leaki-
ness on the accumulation of PpIX and Gd. In fact, [PpIX] better
predicted neovascularization than did Gd.21 Samkoe et al.22
made similar observations in which ex vivo sections from an
orthotopic preclinical glioma model had [PpIX] values that cor-
related with regions of Gd-enhancement seen on in vivo
T1-weighted MRI, but [PpIX] showed superior sensitivity to
predicting tumor vascularity. Unmasking the fluorescent signal
from highly vascularized tumors is critical as these tumors are
more aggressive and tend to migrate beyond the primary site.21 It
may be possible to use the total hemoglobin content and oxygen
saturation of the tissue, which can be calculated from the tissue
absorption spectra, as surrogate intrinsic biomarkers for micro-
vascular density, and indeed these parameters derived in patients
by the point-probe instrument have been shown to increase
further the accuracy of residual glioma tissue detection.24
We are able to extract [PpIX] in vivo by decoupling the
intrinsic fluorescence signal from biophysical and physiological
distorting effects, based on recovering 2-D maps of μa and μ 0s .
This is possible with SFDI, although it has limitations in tissue
with high absorption. Our system was optimized to recover
tissue optical properties in the subdiffusive regime down to a
reduced transport albedo of 0.33.18 Despite implementing
SFDI at higher spatial frequencies than typically used in the dif-
fusion regime, μa and μ 0s may not be as fully decoupled as they
were in our previous phantom study18 that allowed sampling at
spatial frequencies up to 1.7 mm−1. In that study,18 we had
shown that higher spatial frequencies were required to accu-
rately separate absorption from scattering. This is analogous
to choosing shorter source–detector separations in the real
space domain when tissue scattering is high, an optimization
step implemented by the intraoperative probe.19 This was not
possible in the small rat brain in which the highest spatial fre-
quency that our current DMD array and imaging system can
resolve is 1 mm−1 for a 3 cm × 3 cm field of view. For future
preclinical SFDI measurements in the subdiffusive regime, a
higher resolution DMD array such as the 0.9 WQXGA Type
A DMD series from Texas Instruments will be required. This
should not be a significant issue in open-field surgery in
patients, although it may be relevant in, e.g., laparoscopic sur-
gery or endoscopy where the field of view is restricted. Work is
in progress to implement the SFD-qFI system on a surgical
microscope platform for further optimization and first clinical
evaluations.25 Despite some systematic errors in deriving the
optical properties by SFDI under our experimental conditions,
[PpIX] can be retrieved with an accuracy approaching that of the
point-probe qFS.7 While we acknowledge that the rather long
acquisition times applied here will interrupt the surgeon’s
work flow in the operating room, implementing SFDI at one
spatial frequency, referred to as single snap shot imaging
(SSOP), is now possible,26 where imaging and postprocessing
of the modulated images can be recovered in 50 to 100 ms.
As for fluorescence imaging, replacing the CCD sensor with
an EMCCD-based sensor allows PpIX detection down to
10 ng∕ml with exposure times of 5 to 10 ms. Both modifica-
tions, SSOP- and EMCCD-based detection, will facilitate trans-
lating qFI to the operating room.9
Finally, while the objective here was to enhance the accuracy
of state-of-the-art PpIX FGR, which utilizes violet/blue light
excitation, both qualitative PpIX FGR and SFD-qFI are limited
to superficial tumors up to a depth of about 1 mm below the
tissue surface. Our recent clinical implementation of PpIX
FGR under red-light excitation27 has shown additional benefit
by identifying deep-seated tumors located up to 5 mm below
the surface. Hence, we are currently investigating the use of
SFDI using 625-nm excitation light to interrogate subsurface
PpIX-rich tumors and recovering both the depth and the
PpIX concentration at that depth.
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